STOCK Ifnar1tm1Agt/Cnrm

Status

Under development - register interest

EMMA IDEM:13140
Citation informationRRID:IMSR_EM:13140 

Research Resource Identifiers (RRID) are persistent unique ID numbers assigned to help researchers cite key resources (e.g. antibodies, model organisms and software projects) in the biomedical literature to improve transparency and reproducibility in research. See https://www.rrids.org/ for more information.

International strain nameSTOCK Ifnar1tm1Agt/Cnrm
Alternative nameIFNAR
Strain typeTargeted Mutant Strains : Knock-out
Allele/Transgene symbolIfnar1tm1Agt
Gene/Transgene symbolIfnar1

Information from provider

ProviderEleonora Aricò
Provider affiliationCore Facilities, Istituto Superiore di Sanità
Genetic informationMice are homozygous for the knocked out gene encoding interferon alpha/beta receptor 1.
Phenotypic informationHomozygous:
Homozygotes Ifnar1 (IFNAR) knock-out mice lack type I interferon receptor function and are viable, fertile and phenotypically normal but show increased susceptibility to viral infections and diminished cancer immune surveillance.

Heterozygous:
Heterozygous Ifnar1 (IFNAR) knock-out mice are viable, fertile and phenotypically normal. No data are available on their susceptibility to viral infections.
Breeding history129/Sv Ifnar1-/- female mice (A129; Muller et al., Science, 1994) were originally purchased from B&K Universal LTD, UK (now Marshall BioResoures, US).
References
  • Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells.;Castiello Luciano, Sestili Paola, Schiavoni Giovanna, Dattilo Rosanna, Monque Domenica M, Ciaffoni Fiorella, Iezzi Manuela, Lamolinara Alessia, Sistigu Antonella, Moschella Federica, Pacca Anna Maria, Macchia Daniele, Ferrantini Maria, Zeuner Ann, Biffoni Mauro, Proietti Enrico, Belardelli Filippo, Aricò Eleonora, ;2018;Cancer immunology research;6;658-670; 29622580
  • Anticancer Effects of Sublingual Type I IFN in Combination with Chemotherapy in Implantable and Spontaneous Tumor Models.;Ciccolella Maria, Andreone Sara, Mancini Jacopo, Sestili Paola, Negri Donatella, Pacca Anna Maria, D'Urso Maria Teresa, Macchia Daniele, Canese Rossella, Pang Ken, SaiYing Ko Thomas, Decadt Yves, Schiavoni Giovanna, Mattei Fabrizio, Belardelli Filippo, Aricò Eleonora, Bracci Laura, ;2021;Cells;10;; 33917958
Homozygous fertileyes
Homozygous viableyes
Homozygous matings requiredno
Immunocompromisedyes

Information from EMMA

Archiving centreCNR, Consiglio Nazionale delle Ricerche, Monterotondo, Italy
Breeding at archiving centre1 backcross to C57BL/6N

Disease and phenotype information

IMPC phenotypes (gene matching)
  • improved glucose tolerance / IMPC
  • decreased circulating fructosamine level / IMPC
  • decreased monocyte cell number / IMPC
  • decreased KLRG1-positive NK cell number / IMPC
  • increased circulating creatinine level / IMPC
  • abnormal vibrissa morphology / IMPC
  • increased bone mineral content / IMPC
  • increased circulating amylase level / IMPC
MGI phenotypes (allele matching)
  • decreased bone mineral density / MGI
  • increased tumor growth/size / MGI
  • abnormal osteoclast morphology / MGI
  • abnormal response to infection / MGI
  • impaired natural killer cell mediated cytotoxicity / MGI
  • decreased tumor necrosis factor secretion / MGI
  • decreased interferon-alpha secretion / MGI
  • decreased interferon-beta secretion / MGI
  • decreased interleukin-6 secretion / MGI
  • increased susceptibility to bacterial infection induced morbidity/mortality / MGI
  • abnormal inflammatory response / MGI
  • abnormal dendritic cell physiology / MGI
  • increased susceptibility to viral infection / MGI
  • abnormal immunoglobulin level / MGI
  • abnormal cytokine secretion / MGI
  • corneal vascularization / MGI
  • increased susceptibility to viral infection induced morbidity/mortality / MGI
  • abnormal NK cell physiology / MGI
  • altered susceptibility to infection / MGI
  • immune system phenotype / MGI
  • abnormal CD8-positive, alpha-beta T cell physiology / MGI
  • abnormal interferon-gamma secretion / MGI
  • increased circulating interleukin-12 level / MGI
MGI phenotypes (gene matching)
  • decreased bone mineral density / MGI
  • increased leukocyte cell number / MGI
  • altered susceptibility to infection / MGI
  • abnormal inflammatory response / MGI
  • increased incidence of induced tumors / MGI
  • abnormal dendritic cell physiology / MGI
  • increased susceptibility to viral infection / MGI
  • abnormal macrophage physiology / MGI
  • abnormal immunoglobulin level / MGI
  • abnormal cytokine secretion / MGI
  • no phenotypic analysis / MGI
  • increased tumor growth/size / MGI
  • abnormal CD8-positive, alpha-beta T cell physiology / MGI
  • increased incidence of tumors by chemical induction / MGI
  • abnormal osteoclast morphology / MGI
  • abnormal response to infection / MGI
  • impaired natural killer cell mediated cytotoxicity / MGI
  • immune system phenotype / MGI
  • corneal vascularization / MGI
  • abnormal enzyme/coenzyme activity / MGI
  • decreased NK cell number / MGI
  • abnormal interferon-gamma secretion / MGI
  • decreased tumor necrosis factor secretion / MGI
  • decreased interferon-alpha secretion / MGI
  • decreased interferon-beta secretion / MGI
  • increased circulating interleukin-12 level / MGI
  • decreased interleukin-6 secretion / MGI
  • increased susceptibility to bacterial infection induced morbidity/mortality / MGI
  • increased susceptibility to viral infection induced morbidity/mortality / MGI
  • abnormal NK cell physiology / MGI

Literature references

  • Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells.;Castiello Luciano, Sestili Paola, Schiavoni Giovanna, Dattilo Rosanna, Monque Domenica M, Ciaffoni Fiorella, Iezzi Manuela, Lamolinara Alessia, Sistigu Antonella, Moschella Federica, Pacca Anna Maria, Macchia Daniele, Ferrantini Maria, Zeuner Ann, Biffoni Mauro, Proietti Enrico, Belardelli Filippo, Aricò Eleonora, ;2018;Cancer immunology research;6;658-670; 29622580
  • Anticancer Effects of Sublingual Type I IFN in Combination with Chemotherapy in Implantable and Spontaneous Tumor Models.;Ciccolella Maria, Andreone Sara, Mancini Jacopo, Sestili Paola, Negri Donatella, Pacca Anna Maria, D'Urso Maria Teresa, Macchia Daniele, Canese Rossella, Pang Ken, SaiYing Ko Thomas, Decadt Yves, Schiavoni Giovanna, Mattei Fabrizio, Belardelli Filippo, Aricò Eleonora, Bracci Laura, ;2021;Cells;10;; 33917958

Information on how we integrate external resources can be found here

Register interest

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

  • Frozen embryos. Delivered in 4 weeks (after paperwork in place). €1740*
  • Frozen sperm. Delivered in 4 weeks (after paperwork in place). €1740*
  • Rederivation of mice from frozen stock, delivery time available upon request . €3880*

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable).

More details on pricing and delivery times

Practical information

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
Distribution of this strain is subject to a provider MTA. Both signing of the MTA and submission of the online EMMA Mutant Request Form are required before material can be shipped.

EMMA conditions
Legally binding conditions for the transfer

Other EMMA strains

Not found what you were looking for? Search here for other strains available from EMMA.


Search
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).